Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

ImmunoGen to develop route for Genentech

May 15, 2006 | A version of this story appeared in Volume 84, Issue 20

ImmunoGen will work with Genentech to create a commercial manufacturing process for Genentech's trastuzumab-DM1, a cancer treatment based on ImmunoGen's tumor-activated prodrug (TAP) technology. The agreement increases to $44 million the amount that ImmunoGen can earn under an existing pact with Genentech. In a TAP compound, a tumor-targeting antibody is linked to a cytotoxic small-molecule agent. ImmunoGen says it has manufactured numerous TAP compounds at its Norwood, Mass., facility.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.